- $174.27m
- $181.28m
- €38.18m
- 46
- 84
- 21
- 49
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.57 | ||
| Price to Tang. Book | 3.03 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.82 | ||
| EV to EBITDA | 6.25 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.12% | ||
| Return on Equity | 25.91% | ||
| Operating Margin | 28.5% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 40.96 | 7.76 | 85.58 | 26.57 | 38.18 | n/a | n/a | 38.49% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Directors
- Jean-Francois Mouney CHM (65)
- Xavier Guille Des Buttes NEC (79)
- Pascal Prigent CEO (53)
- Thomas Baetz CFO (47)
- Dean Hum COO (58)
- Nathalie Huitorel EVP (59)
- Stefanie Magner CCO (40)
- Carol Addy OTH (61)
- Pascal Caisey OTH (53)
- Suneil Hosmane OTH (39)
- Jean-Christophe Marcoux OTH (44)
- Philippe Motte OTH (61)
- Laurent Lannoo SEC (51)
- Florence Sejourne DRC (49)
- Eric Baclet IND (79)
- Frederic Desdouits IND (54)
- Katherine Kalin IND (58)
- Catherine Larue IND (65)
- Anne-Helene Monsellato IND (53)
- Jean-Francois Tine IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- September 15th, 1999
- Public Since
- December 19th, 2006
- No. of Employees
- 169
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 49,834,983
- Address
- Parc Eurasante 885 avenue Eugene Avinee, LOOS, 59120
- Web
- https://www.genfit.fr/
- Phone
- +33 320164000
- Auditors
- Ernst & Young et Autres
Similar to GNFT
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
As of Today at 20:47 UTC, shares in Genfit SA are trading at $3.51. This share price information is delayed by 15 minutes.
Shares in Genfit SA last closed at $3.51 and the price had moved by -3.31% over the past 365 days. In terms of relative price strength the Genfit SA share price has underperformed the S&P500 Index by -9.08% over the past year.
There is no consensus recommendation for this security.
Find out moreGenfit SA does not currently pay a dividend.
Genfit SA does not currently pay a dividend.
Genfit SA does not currently pay a dividend.
To buy shares in Genfit SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.51, shares in Genfit SA had a market capitalisation of $174.27m.
Here are the trading details for Genfit SA:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: GNFT
Based on an overall assessment of its quality, value and momentum Genfit SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genfit SA. Over the past six months, its share price has underperformed the S&P500 Index by -34.52%.
As of the last closing price of $3.51, shares in Genfit SA were trading -16.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genfit SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Genfit SA's management team is headed by:
- Jean-Francois Mouney - CHM
- Xavier Guille Des Buttes - NEC
- Pascal Prigent - CEO
- Thomas Baetz - CFO
- Dean Hum - COO
- Nathalie Huitorel - EVP
- Stefanie Magner - CCO
- Carol Addy - OTH
- Pascal Caisey - OTH
- Suneil Hosmane - OTH
- Jean-Christophe Marcoux - OTH
- Philippe Motte - OTH
- Laurent Lannoo - SEC
- Florence Sejourne - DRC
- Eric Baclet - IND
- Frederic Desdouits - IND
- Katherine Kalin - IND
- Catherine Larue - IND
- Anne-Helene Monsellato - IND
- Jean-Francois Tine - IND